# Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

> **NCT03967249** · PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 39 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** IONIS GHR-LRx
- **DRUG:** Somatostatin Receptor Ligand (SRL)

## Key facts

- **NCT ID:** NCT03967249
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-25
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-07-07
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2023-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03967249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03967249, "Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03967249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*